Intelligence Profile
Research Papers
Research Papers and Clinical Trials
The current evidence on BMAC (Bone Marrow Aspirate Concentrate) joint therapy consists primarily of recent publications from 2025-2026, though several clinical trials have faced completion challenges.
Published Research
A 2026 randomized controlled trial published in Stem Cell Research & Therapy directly compared bone marrow aspirate clot versus bone marrow aspirate concentrate in patients with grade 3 and 4 knee osteoarthritis, though specific sample sizes and outcomes are not detailed in the available information.
Another 2026 randomized controlled trial in The American Journal of Sports Medicine examined BMAC's role in enhancing osseous integration of fresh osteochondral allografts in knee procedures, suggesting potential benefits for surgical applications.
A comparative study published in The Medical Journal of Malaysia (2026) found that umbilical cord-derived mesenchymal stem cells showed earlier clinical improvement compared to BMAC with scaffold in knee cartilage injuries. This Phase 1 feasibility and Phase 2 randomized controlled trial suggests BMAC may be less effective than some alternative cell therapies.
Several review articles from 2026 address broader contexts around orthobiologic therapies, including treatment options for ACL-injured athletes with cartilage damage and the need for protocol standardization in cell therapies for osteoarthritis. One review specifically examined internet promotion of orthobiologics by orthopedic surgeons, highlighting potential gaps between marketing claims and available evidence.
Clinical Trial Status
The clinical trial landscape shows mixed progress. Multiple studies have been withdrawn or terminated, including trials examining BMAC for calcaneus fractures, ankle osteoarthritis, and severe hip/knee osteoarthritis awaiting joint replacement surgery.
One notable completed Phase 3 trial (MILES study) investigated stem cell therapy for osteoarthritis more broadly, though specific results are not available in the provided evidence. An early-phase orthobiological therapies trial is listed as not yet recruiting.
Evidence Limitations
The available evidence provides limited detail on study sample sizes, specific outcome measures, or long-term follow-up data. The high rate of withdrawn or terminated trials suggests potential challenges in conducting BMAC research, though the reasons for these study discontinuations are not specified in the available information.
This information is for educational purposes only and should not be considered personalized medical advice. Consult with a qualified healthcare provider for treatment decisions.